#ProstateCancer Archives

Unveiling Progress in Immunotherapy and Pathological Diagnosis for Urological Cancers: Insights from Dr. Félix Guerrero Ramos and Dr. Xuefeng Qiu at EAU Congress 2024

By Mourabit Halima 2024.05.09

In a significant gathering at the European Association of Urology (EAU) Congress 2024, held in the vibrant city of Paris, two esteemed figures in the field of urology, Dr. Félix…

EAU24 Interview丨Dr. Junlong Zhuang and Dr. Bertrand Tombal jointly interpret the ARASENS study and explore intensive treatment strategies for mHSPC

By Mourabit Halima 2024.04.29

Editor's note: In recent years, on the basis of androgen deprivation therapy (ADT), new endocrine therapies such as AR pathway inhibitors have become standard treatments for patients with metastatic hormone-sensitive…

ASCO-GU Interview | Dr. Tao Xu: Current status of precision treatment of prostate cancer and application of genetic testing

By Mourabit Halima 2024.03.05

Editor's Note: On January 25, 2024, the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) marked its 20th anniversary in San Francisco, USA. On the occasion of the 20th…

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: Following the breakthrough of the PROfound study, which marked the beginning of precision treatment for prostate cancer, the PROpel study has further extended the application of PARP inhibitors…

ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC

By Mourabit Halima 2024.03.04

Editor's note: At the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) held recently, data on patients with homologous recombination repair mutations (HRRm) from the PROpel study…

ASCO-GU Interview | Dr. Qiang Wei: Embracing the Era of Precision Treatment, Offering Personalized Treatment Through Multidisciplinary Management

By Mourabit Halima 2024.03.04

Editor's Note: Prostate cancer is the most common "silent killer" threatening men's health worldwide, with traditional treatments primarily involving surgery, radiation therapy, chemotherapy, and hormonal therapy. In recent years, the…

ESMO Expert Commentary | Dr. Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

By Mourabit Halima 2024.01.17

Editor's Note: Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled…

#ProstateCancer

Unveiling Progress in Immunotherapy and Pathological Diagnosis for Urological Cancers: Insights from Dr. Félix Guerrero Ramos and Dr. Xuefeng Qiu at EAU Congress 2024

EAU24 Interview丨Dr. Junlong Zhuang and Dr. Bertrand Tombal jointly interpret the ARASENS study and explore intensive treatment strategies for mHSPC

ASCO-GU Interview | Dr. Tao Xu: Current status of precision treatment of prostate cancer and application of genetic testing

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC

ASCO-GU Interview | Dr. Qiang Wei: Embracing the Era of Precision Treatment, Offering Personalized Treatment Through Multidisciplinary Management

ESMO Expert Commentary | Dr. Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

Navigating Prostate Cancer with Precision: Next-Generation Imaging Insights from Professor Silke Gillessen

Prostate Cancer: Unveiling the Roles of Germline and Tumor Testing with Professor Kim Nguyen N. Chi

🔬 Navigating Advanced Prostate Cancer: A Deep Dive with Dr. Silke Gillessen